PAVmed Secures $7 Million Convertible Note Financing
06 août 2020 09h27 HE
|
PAVmed Inc.
NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today...
PAVmed Subsidiary Lucid Diagnostics Receives Preliminary Payment Determination for EsoGuard™ Esophageal DNA Test
11 juin 2020 09h30 HE
|
PAVmed Inc.
NEW YORK, June 11, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that its...
PAVmed to Hold Business Update Conference Call on May 21, 2020
11 mai 2020 09h30 HE
|
PAVmed Inc.
NEW YORK, May 11, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the...
PAVmed to Hold Business Update Conference Call on April 9, 2020
24 mars 2020 09h30 HE
|
PAVmed Inc.
NEW YORK, March 24, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the...
PAVmed Announces FDA 510(k) Re-submission for its CarpX™ Minimally Invasive Carpal Tunnel Device
09 mars 2020 09h30 HE
|
PAVmed Inc.
Incorporates data from successful clinical safety study in which all patients met pre-specified safety and effectiveness endpoints NEW YORK, March 09, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq:...
PAVmed Subsidiary Lucid Diagnostics Partners with Fred Hutchinson Cancer Research Center to Evaluate Barrett’s Esophagus (BE) Progression Biomarkers Using EsoCheck™
20 févr. 2020 09h30 HE
|
PAVmed Inc.
Lucid secures exclusive option to license biomarker technology to detect progression from nondysplastic to dysplastic BE using EsoCheck to allow curative ablation before deadly esophageal cancer...
PAVmed Receives Formal Notification of Nasdaq Continued Listing Compliance
13 janv. 2020 09h30 HE
|
PAVmed Inc.
NEW YORK, Jan. 13, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it has...
PAVmed Announces First Human CarpX™ Procedures
20 mai 2019 09h30 HE
|
PAVmed Inc.
First nine patients undergo successful CarpX procedures as part of FIH clinical safety study NEW YORK, May 20, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or...
PAVmed to Hold Business Update Conference Call on May 21, 2019
06 mai 2019 09h30 HE
|
PAVmed Inc.
NEW YORK, May 06, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the...
PAVmed to Hold Business Update Conference Call on April 4, 2019
21 mars 2019 07h30 HE
|
PAVmed Inc.
NEW YORK, March 21, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the...